Abbott Laboratories is a well-known global healthcare company. Its stock quote as of August 10, 2020 shows it to be trading at 106.74 with a change of 0.6222% and market cap of 186 billion USD.
An analysis of Abbott laboratories Revenue data for the last few quarters reveals that revenues have increased steadily over the past year except for the current quarter ending March 2021, where revenue was estimated at 96 billion USD but reported zero. The quarterly revenues for the previous 4 quarters ending June 2020, March 2020, December 2019 and September 2019 were 11.26 billion USD, 11.89 billion USD, 10.29 billion USD and 1.15 billion USD respectively.
This indicates that Abbott Laboratories has been performing well financially in the last few quarters and its performance has continued to improve since September 2019 when its reported revenue was 1.15 mln USD which increased to 11.89 bln USD in March 2021 despite current quarter’s revenue being reported as 0 due to Covid-19 pandemic related challenges faced by the company during this period of time.
Overall, one can conclude that Abbott Laboratories is doing relatively well financially despite lower than expected results in the current quarter due to pandemic related challenges and is seeing steady growth over the past year with increasing revenues each quarter except for the most recent one which still shows healthy potential for further growth in near future with estimated revenue for next quarter walking back up to 9.63 bln USD from 0 reported in current quarter
